Trial Profile
A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Feb 2020
Price :
$35
*
At a glance
- Drugs TAS 114 (Primary) ; Gimeracil/oteracil/tegafur
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Taiho Pharmaceutical
- 03 Feb 2020 Status changed from active, no longer recruiting to completed.
- 13 Apr 2018 According to a Taiho Oncology media release, data from this trial is being presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR).
- 02 Dec 2016 Status changed from recruiting to active, no longer recruiting, according to the results presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics